Ozempic-style drugs linked to major slowdown in cancer spread, new study finds

A new study suggests GLP-1 weight-loss drugs like semaglutide and tirzepatide may significantly slow the progression of obesity-related cancers such as lung, breast, colorectal, and liver cancers. Conducted by Cleveland Clinic and to be presented at the 2026 ASCO Annual Meeting, the retrospective analysis found GLP-1 users had up to 50% lower risk of cancer advancing to stage 4 compared to patients taking DPP-4 inhibitors.